In light of the pandemic situation events until September 2021 are cancelled. We will inform customers directly when the events are rescheduled.    
COVID CANCELLED: Project Management in Human Resources,   Boston MA, Jan 6-8, 2021
COVID CANCELLED: InterDrone, The International Drone Conference,   Cambridge MA, Jan 11-13, 2021
COVID CANCELLED: Supplier Management for Medical Device Manufacturers,   Cambridge MA, Feb 2-4, 2021
COVID CANCELLED: US Immigration Compliance Strategies,   Boston MA, Feb 15-18, 2021
COVID CANCELLED: Project Management Training,   Boston MA, Mar 3-5, 2021
COVID CANCELLED: Internal Audit, Fraud Risk Assessment Workshop,   Boston MA, Mar 22-25, 2021
COVID CANCELLED: Agile / Scrum Training,   Boston MA, Apr 12-14, 2021
COVID CANCELLED: Validation, Verification and Transfer of Analytical Methods,   Boston MA, Apr 19-21, 2021
COVID CANCELLED: Computer System Validation - Reduce Costs and Avoid 483s,   Boston MA, May 10-12, 2021
COVID CANCELLED: SharePoint Technology Conference,   Boston MA, May 26-28, 2021
COVID CANCELLED: Employment Laws Certificate Program,   Boston MA, Jun 7-9, 2021
Following events are tentatively planned but may be rescheduled, based on CDC guidelines or attendee registration interest .    
TENTATIVE: 21 CFR Part 11 Compliance,   Boston MA, Sep 22-24, 2021
TENTATIVE: Quality Control Laboratory Compliance,   Boston MA, Oct 6-8, 2021
TENTATIVE: Analytical Instrument Qualification and System Validation,   Boston MA, Nov 15-17, 2021
TENTATIVE: FDA's New Import Program for 2021,   Boston MA, Dec 7-9, 2021

Boston Professional Events List

2nd ADC Target Selection Summit

Dec 06, 2022 - 09:00 AM - Dec 08, 04:00 PM
Hanson Wade
Hilton Boston Logan Airport
One Hotel Drive,

ZIP: 02128
Phone: +1 617 455 4188

Ticket Price: USD 2499.00 - USD 4697.00

With no room for error in the highly competitive ADC market and no going back after you have selected your target, it is vital that drug developers optimally triangulate the linker-payload, target and indication to develop an ADC that can have the biggest impact on patients.

Recent exciting developments in linker-payload technologies and clinical efficacy in low-expressed tumors have propelled this conversation to the forefront of mind. We are at the cusp of seeing clinical improvements on previously validated targets, witnessing success on targets where previous ADCs have failed and engaging novel targets, widening the application of ADCs beyond what was thought.

The 2nd ADC Target Selection Summit will provide you an A-Z coverage of the key considerations that ADC developers are making when it comes to target selection including how to think about the payload and target holistically, understand expression profiles, and how proteomic and bioinformatic technologies can deepen our understanding of targets going forward.

Don't miss your one-stop shop to gain exclusive insights as ADC enthusiasts with backgrounds in target ID and validation, cancer biology and drug discovery come together to address core challenges in the target selection process.

Join 80+ peers from across the ADC landscape to transform your target selection strategies to ensure you are maximizing the therapeutic window of your ADC and improving patients outcomes.

Tickets: https://go.evvnt.com/1261856-2?pid=1052
Brochure: https://go.evvnt.com/1261856-3?pid=1052

Drug Developer - Conference + Workshop Day: USD 3897.00,
Drug Developer - Conference Only: USD 2899.00,
Service Provider - Conference + Workshop Day: USD 4697.00,
Service Provider - Conference Only: USD 3499.00,
Academic - Conference + Workshop Day: USD 3297.00,
Academic - Conference Only: USD 2499.00

Speaker Details

Jagath Reddy Junutula, President, Chief Executive Officer and Co-Founder, Aarvik Therapeutics, Yu Shen, Director, Oncology Discovery, AbbVie, Adrian Hobson, Senior Research Fellow, Drug Discovery Science and Technology Antibody-Drug Conjugates, AbbVie, Jixin Wang, Associate Director, Oncology Bioinformatics, AstraZeneca, John Lambert, Consultant, Attager Consulting, Rakesh Dixit, Chief Executive Officer, Bionavigen, Sayumi Yamazoe, Senior Principal Scientist, Bristol-Myers Squibb, Seema Kantak, Senior Vice President, Biotherapeutics, Exelixis, Christopher Shelton, Scientific Director, Tumor Cell Targeting Research Unit, GlaxoSmithKline, Aniko Palfi, Director, Biochemistry and Cell Biology, Heidelberg Pharma Research GmbH, Ed Ha, Head, ADC Innovation, Iksuda Therapeutics, Robert Lutz, Chief Scientific Officer, Iksuda Therapeutics, Robert Lutz, Chief Scientific Officer, Iksuda Therapeutics, Thomas Nittoli, Senior Director, R and D Chemistry, Regeneron, John DaSilva, Associate Director, Oncology and Immuno-Oncology, Regeneron, Robert Lawrence, Senior Scientist, Seagen, Annette Vogl, Director, Biology and Translational Research, Tubulis GmbH, Jamie Rich, Director, Antibody- Drug Conjugate Technology and Therapeutic Development, Zymeworks

Event Categories
Keywords: conference


Events Calendar

27 28 29 30 1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31


VIP Life Time Subscription to our Newsletters!